Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients
- Conditions
- De Novo Kidney Transplant Recipients
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 35
- Registration Number
- NCT00312143
A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
- Conditions
- Hypertension
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 582
- Registration Number
- NCT00311740
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
- Conditions
- Encephalitis, Tick-Borne
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 300
- Registration Number
- NCT00311441
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects
- Conditions
- Pandemic Influenza Disease
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2007-03-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 520
- Registration Number
- NCT00311480
- Locations
- 🇮🇹
G. D'Annunzio University, Chieti, Italy
🇮🇹Department of Health Sciences, Genoa, Italy
🇮🇹ASL Lanciano-Vasto, Lanciano, Italy
Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults
- Conditions
- Encephalitis, Tick-Borne
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2007-03-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 179
- Registration Number
- NCT00311493
Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months
- Conditions
- Influenza
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2006-09-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 270
- Registration Number
- NCT00311428
- Locations
- 🇫🇮
University of Tampere Medical School, Tampere, Finland
SPP100 Dose Finding Study in Japan
- Conditions
- Hypertension
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 445
- Registration Number
- NCT00311012
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Kinetics of B Cell Response in Infants Menjugate Vaccination
- Conditions
- Prevention of Meningococcal Infection
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 75
- Registration Number
- NCT00310700
- Locations
- 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, Oxon, United Kingdom
Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)
- Conditions
- Influenza
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2006-09-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 600
- Registration Number
- NCT00310648
- Locations
- 🇨🇳
Nanning, Guangxi, China
Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age
- Conditions
- Prevention of Meningococcal Infection
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2007-03-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00310674
- Locations
- 🇮🇹
Istituto di Pediatria, Università degli Studi di Milano, Milano, Italy